| scholarly article | Q13442814 |
| P50 | author | Yasuhiro Fujiwara | Q92992472 |
| P2093 | author name string | Toshio Watanabe | |
| Noriko Kamata | |||
| Fumio Tanaka | |||
| Hirokazu Yamagami | |||
| Tetsuya Tanigawa | |||
| Yasuaki Nagami | |||
| Koji Otani | |||
| Kazuki Kakimoto | |||
| Koichi Taira | |||
| Shuhei Hosomi | |||
| Yu Nishida | |||
| Naoko Sugita | |||
| Tomomi Yukawa | |||
| Shigehiro Itani | |||
| P2860 | cites work | Early corticosteroids requirement after the diagnosis of ulcerative colitis diagnosis can predict a more severe long-term course of the disease - a nationwide study of 1035 patients | Q48267292 |
| Early drug and anti-infliximab antibody levels for prediction of primary nonresponse to infliximab therapy | Q48327816 | ||
| Serum interleukin-6 level is associated with response to infliximab in ulcerative colitis | Q49682864 | ||
| Risk of colectomy in patients with ulcerative colitis under thiopurine treatment. | Q50473979 | ||
| Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. | Q53122367 | ||
| Tacrolimus for remission induction in ulcerative colitis: Mayo endoscopic subscore 0 and 1 predict long-term prognosis. | Q53608268 | ||
| Steroid-unresponsive acute attacks of inflammatory bowel disease: immunomodulation by tacrolimus (FK506). | Q54121491 | ||
| Long-term outcome after infliximab for refractory ulcerative colitis | Q57265403 | ||
| The Natural History of Corticosteroid Therapy for Ulcerative Colitis in Children | Q59684197 | ||
| The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study | Q74315857 | ||
| Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine | Q24685403 | ||
| Colectomy rate in steroid-refractory colitis initially responsive to cyclosporin: a long-term retrospective cohort study | Q33280166 | ||
| Cyclosporine in severe ulcerative colitis refractory to steroid therapy | Q34060783 | ||
| A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis | Q35768942 | ||
| Neutrophil-to-Lymphocyte Ratio for Predicting Loss of Response to Infliximab in Ulcerative Colitis | Q36246295 | ||
| The use of traditional and newer calcineurin inhibitors in inflammatory bowel disease | Q37816246 | ||
| Calcineurin inhibitor nephrotoxicity: a review and perspective of the evidence | Q38116657 | ||
| A Comparison of Short- and Long-Term Therapeutic Outcomes of Infliximab- versus Tacrolimus-Based Strategies for Steroid-Refractory Ulcerative Colitis. | Q38287132 | ||
| Efficacy and Safety of Tacrolimus Therapy for Active Ulcerative Colitis; A Systematic Review and Meta-analysis. | Q38662186 | ||
| Systematic Review and Meta-Analysis: Infliximab or Cyclosporine as Rescue Therapy in Patients With Severe Ulcerative Colitis Refractory to Steroids | Q38726448 | ||
| A comparison of short-term therapeutic efficacy between infliximab and tacrolimus for moderate to severe ulcerative colitis | Q38950167 | ||
| Natural History of Adult Ulcerative Colitis in Population-based Cohorts: A Systematic Review. | Q39381231 | ||
| Long-term Outcomes in Steroid-refractory Ulcerative Colitis Treated with Tacrolimus Alone or in Combination with Purine Analogues | Q40485898 | ||
| Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis | Q41128447 | ||
| Intravenous cyclosporin in ulcerative colitis: a five-year experience | Q41671378 | ||
| Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis | Q43787358 | ||
| Ulcerative colitis: patient characteristics may predict 10-yr disease recurrence in a European-wide population-based cohort | Q44024340 | ||
| Survival analysis using inverse probability of treatment weighted methods based on the generalized propensity score | Q44201756 | ||
| Mucosal healing with oral tacrolimus is associated with favorable medium- and long-term prognosis in steroid-refractory/dependent ulcerative colitis patients. | Q45831311 | ||
| One-year maintenance outcomes among patients with moderately-to-severely active ulcerative colitis who responded to induction therapy with adalimumab: subgroup analyses from ULTRA 2. | Q45913034 | ||
| Albumin as a prognostic marker for ulcerative colitis | Q47095157 | ||
| Long-term outcome of patients with steroid-refractory acute severe UC treated with ciclosporin or infliximab. | Q48095368 | ||
| P433 | issue | 16 | |
| P921 | main subject | azathioprine | Q18939 |
| P304 | page(s) | 2305-2313 | |
| P577 | publication date | 2019-05-22 | |
| P1433 | published in | Internal Medicine | Q6047666 |
| P1476 | title | Azathioprine Is Useful for Maintaining Long-term Remission Induced by Tacrolimus for the Treatment of Ulcerative Colitis: An Inverse Probability of a Treatment Weighing Analysis | |
| P478 | volume | 58 |
Search more.